Formation of We Are Pioneer Group, a new company borne from merger of BioCity and Knowledge Factory, creates a new integrated business combining early-stage life science investing and accelerator programme with real estate investment platform managing 2.6 million square feet of labs We...
BioCity investee, Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund....
BioCity, the pioneering life science incubator and business collective, in partnership with education charity Ignite!, is welcoming back primary school students to join their Lab_13 programme. Lab_13, started by Ignite! in 2009, is an initiative in which children manage their own investigations and scientific research, where...
Today Maxwellia, which is poised to transform the UK’s “self-care market”, has secured an approx. €3.7 million investment in a funding round led by Praetura Ventures. Maxwellia aims to give people easier and faster access to the treatments they need by converting prescription-only medicines to versions that can be bought...
Phenotypeca is pleased to report that it has purchased a substantial amount of laboratory equipment from Nottingham biotechnology company Albumedix, a recognised global leader in recombinant human albumin (rHA), specialising in the enablement of advanced therapies. This allows Phenotypeca to equip its next-generation yeast technology laboratory...
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, is pleased to announce the successful completion of its oversubscribed Placing. The Placing was enlarged to accommodate additional investor interest from both new and existing investors. The Placing has raised gross proceeds of £9.0 million (before commission and expenses)...
Over the past few years Sygnature Discovery has acquired two of the UK’s most respected CROs: RenaSci and XenoGesis. As of this month, the teams and services provided by these two companies will be fully integrated under the Sygnature Discovery brand, creating one of the most...
BioCity based Scotbio has struck a university partnership to look at ways of expanding its process for manufacturing natural nutritional ingredients into the production of treatments for coronaviruses and other pathogens. A £100,000 award from Medical Research Scotland will fund a four-year PhD project in which the Infection...
RenaSci was founded in 2001 by Dr Sharon Cheetham, Dr Rob Jones and Professor David Heal, providing an integrated blend of in vivo pharmacology consultancy and experimental services, helping clients from all sectors of the pharmaceutical and biotech industry to maximise their research productivity and streamline drug...
Image: Professors Alessio Ciulli and Sir Mike Ferguson Drugs development firm Amphista Therapeutics has unveiled a £38 million investment that will enhance its work to develop treatments for a range of diseases. The company is a spinout from Professor Alessio Ciulli’s labs at the University of Dundee’s School...